Hot Investor Mandate 2: Pharma Seeks Therapeutics in Cardiology, Metabolism, Oncology, and CNS

25 Aug

A Europe-based pharma firm is interested in partnerships with with early-stage biotech companies, usually structured in the form of rights, co-marketing, or R&D collaborations. The firm is open to partnering with companies globally.

The firm focuses on 5 disease areas; cardiovascular disease (heart failure, ischemia, atrial fibrillation), metabolism (type 2 diabetes and complications of diabetes), oncology (apoptosis, immunotherapy, proliferation & differentiation pathways, protein degradation, and epigenetics), CNS (cognitive impairment, neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, multiple sclerosis, and ALS), and rheumatology (osteoarthritis, inflammatory and immune diseases, and muscle pathologies). Within these disease areas, the firm focuses on unmet medical needs and will consider partnering on any molecule type (small molecule, biologic or cell therapy), but is only interested in novel therapeutic products; the firm does not invest in drug delivery or biosimilars. The firm will consider opportunities from target stage to late clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: